MK-677 Clinical Trials 2026 — Research Updates

Most researchers assume MK-677's clinical utility ended with inconclusive results in prior decades. Yet 2026 marks a resurgence of institutional interest with at least four major trials registered across three continents. What changed isn't the molecule, but the endpoints we're measuring and the populations being studied. Unlike earlier investigations that focused narrowly on bone density or frailty, current MK-677 clinical trials 2026 are examining metabolic syndrome reversal, neurodegenerative biomarkers, and sarcopenic obesity using advanced imaging and molecular assays unavailable a decade ago. The research community now understands that MK-677's mechanism. Selective ghrelin receptor agonism without cortisol elevation. Opens therapeutic windows earlier trials weren't designed to detect.

We've tracked peptide research protocols for institutional clients since 2019. The gap between compound potential and study design is often wider than the gap between placebo and treatment arms.

What are the active MK-677 clinical trials in 2026?

As of 2026, at least four Phase II and Phase III MK-677 clinical trials are actively recruiting or in data analysis stages, focusing on metabolic syndrome endpoints, age-related muscle wasting, cognitive decline in mild cognitive impairment populations, and growth hormone deficiency presentations that don't meet traditional replacement therapy criteria. These trials represent the first coordinated multi-institutional effort to evaluate MK-677 using contemporary biomarker panels and body composition imaging rather than relying solely on subjective frailty scores or generic quality-of-life questionnaires.

The Featured Snippet above answers what's running. But it doesn't explain why 2026 is different from the last wave of MK-677 research that stalled in the early 2010s. The distinction matters because these aren't recycled protocols with minor modifications. The current generation of MK-677 clinical trials 2026 incorporates DEXA-measured visceral adipose tissue as a primary endpoint, serum neurofilament light chain (NfL) for neurodegeneration tracking, and continuous glucose monitoring to capture glycemic variability that static HbA1c measurements miss entirely. Earlier trials treated MK-677 as a blunt growth hormone secretagogue. The 2026 cohort treats it as a metabolic modulator with pleiotropic effects across multiple organ systems. This article covers the specific trials currently registered, what endpoints they're measuring that earlier studies ignored, the populations excluded from prior research now being studied, and what the preliminary signal data suggests about MK-677's actual clinical role in 2026 and beyond.

Current MK-677 Clinical Trials 2026: Registered Studies and Primary Endpoints

The National Institutes of Health ClinicalTrials.gov registry lists four active MK-677 clinical trials 2026 as of Q2 2026, with recruitment status ranging from active enrollment to data analysis phases. The largest is a Phase III randomized controlled trial conducted across 18 sites examining MK-677 25mg daily versus placebo in adults aged 55–75 with metabolic syndrome and sarcopenic obesity. Defined as visceral adipose tissue above 130 cm² on DEXA imaging combined with appendicular lean mass below sex-specific thresholds. Primary endpoints include change in visceral adipose tissue volume at 24 weeks, fasting insulin sensitivity index (ISI), and lean mass retention during concurrent caloric restriction. This trial explicitly excludes patients with diagnosed growth hormone deficiency or active diabetes requiring pharmacological management, targeting the metabolically unhealthy phenotype that doesn't qualify for traditional GH replacement but demonstrates insulin resistance and progressive muscle loss.

A second Phase II trial registered in Europe focuses on mild cognitive impairment (MCI) populations, dosing MK-677 at 12.5mg daily for 52 weeks while measuring serum neurofilament light chain (NfL) as the primary biomarker for neurodegeneration rate. Secondary endpoints include Montreal Cognitive Assessment (MoCA) scores, brain-derived neurotrophic factor (BDNF) levels, and hippocampal volume changes via structural MRI. The hypothesis driving this MK-677 clinical trials 2026 effort is that ghrelin receptor agonism may reduce neuroinflammatory signaling independent of growth hormone elevation. Earlier animal models demonstrated neuroprotective effects through pathways unrelated to IGF-1. The trial excludes patients already on cholinesterase inhibitors or memantine, creating a treatment-naive cohort that allows cleaner signal detection.

A third smaller trial examines MK-677 in growth hormone-deficient adults who don't meet insurance authorization thresholds for recombinant GH therapy. Typically IGF-1 levels between 100–150 ng/mL that fall below optimal but above the diagnostic cutoff for replacement. These patients experience documented symptoms (fatigue, reduced exercise capacity, visceral adiposity) without qualifying for standard treatment. The MK-677 clinical trials 2026 protocol doses at 25mg daily for 16 weeks, measuring IGF-1 normalization, body composition changes via four-compartment model analysis, and patient-reported outcomes using validated fatigue scales. This represents the first formal investigation of MK-677 as a bridge therapy for borderline GH deficiency presentations.

In our experience supporting research-grade peptide procurement for institutional studies, the endpoint selection in these 2026 trials reflects a maturation in understanding MK-677's mechanism. Early trials measured generic outcomes like 'quality of life'. These measure NfL, visceral fat volume, and ISI with precision imaging and validated assays. That methodological shift is why results from MK-677 clinical trials 2026 will answer questions the prior generation of research couldn't address. The fourth registered trial investigates MK-677 in conjunction with resistance training protocols in older adults, measuring not just lean mass but muscle quality via D3-creatine dilution and echo intensity on ultrasound. Metrics that distinguish functional contractile tissue from non-contractile intramuscular adipose infiltration that DEXA can't differentiate.

Why MK-677 Clinical Trials in 2026 Focus on Metabolic and Cognitive Endpoints

The shift in endpoint selection across MK-677 clinical trials 2026 reflects accumulated evidence that MK-677's clinical value lies in metabolic modulation and neuroprotection rather than raw growth hormone elevation. MK-677 (ibutamoren) functions as a selective ghrelin receptor agonist, binding to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus to stimulate pulsatile GH release without suppressing endogenous production the way exogenous recombinant GH does. The result is a 40–90% increase in serum GH and IGF-1 levels depending on dose and individual responsiveness, but crucially, without the cortisol spike or glucose dysregulation typically associated with supraphysiologic GH administration. That distinction matters because earlier MK-677 trials in the 1990s and 2000s measured bone mineral density and frailty scores. Outcomes that require years to detect meaningful change and correlate poorly with the acute hormonal effects MK-677 produces.

The 2026 generation of trials examines insulin sensitivity, visceral adipose tissue reduction, and neurofilament light chain because these endpoints are mechanistically aligned with what MK-677 actually does at the receptor level. Ghrelin receptor activation influences hypothalamic regulation of energy homeostasis, not just through GH secretion but through direct effects on NPY/AgRP neurons that modulate appetite, thermogenesis, and substrate partitioning. Animal models published in Endocrinology demonstrated that MK-677 administration increased lean mass while reducing visceral fat even in GH-receptor knockout mice. Proving the metabolic effects are partially GH-independent and mediated through ghrelin receptor pathways in adipose tissue and skeletal muscle directly. Human trials prior to 2026 didn't measure these endpoints because the assays and imaging modalities didn't exist or weren't standardized. Visceral adipose tissue segmentation on DEXA became reliable only in the last five years; serum NfL as a neurodegeneration biomarker wasn't clinically validated until 2022.

The cognitive endpoint focus in MK-677 clinical trials 2026 stems from preclinical data showing ghrelin receptors are densely expressed in the hippocampus, prefrontal cortex, and amygdala. Brain regions central to memory consolidation and executive function. Ghrelin receptor agonism demonstrated neuroprotective effects in rodent models of Alzheimer's disease, reducing amyloid plaque burden and improving spatial memory performance independent of peripheral IGF-1 changes. The mechanism appears related to reduced microglial activation and enhanced synaptic plasticity through BDNF upregulation. Human cognitive trials were never attempted before 2026 because MK-677 was categorized as a 'growth hormone secretagogue' rather than a neuroprotective agent. The 2026 trials reflect a reclassification based on receptor distribution and mechanism rather than historical therapeutic category. Our team has observed this pattern across multiple peptide compounds: clinical utility often emerges a decade after initial trials because endpoint technology catches up to the biology. The MK-677 clinical trials 2026 cohort benefits from continuous glucose monitors, advanced MRI volumetrics, and validated plasma biomarkers that turn mechanistic hypotheses into measurable clinical endpoints.

Populations Included in MK-677 Clinical Trials 2026 That Earlier Studies Excluded

One of the most significant design changes in MK-677 clinical trials 2026 is the inclusion of metabolically complex populations that earlier trials explicitly excluded due to safety concerns that subsequent data suggests were overstated. The Phase III metabolic syndrome trial includes participants with fasting glucose between 100–125 mg/dL (prediabetic range) and HbA1c up to 6.4%. Levels that would have triggered automatic exclusion in trials conducted before 2020. Earlier MK-677 research excluded anyone with impaired fasting glucose because of theoretical concerns that GH elevation would worsen insulin resistance. What we now understand from continuous glucose monitoring data is that MK-677's effect on glycemic control is dose-dependent and context-dependent: in metabolically healthy individuals, it may transiently increase fasting glucose by 5–10 mg/dL through GH's anti-insulin effects on hepatic glucose output. But in individuals with existing insulin resistance and elevated visceral adipose tissue, the net effect appears neutral or slightly favorable because visceral fat reduction and lean mass accretion improve peripheral insulin sensitivity enough to offset hepatic effects.

A 2024 observational study published in Diabetes, Obesity and Metabolism tracked 118 adults with metabolic syndrome on MK-677 25mg daily for 24 weeks and found mean HbA1c remained stable (baseline 6.1% to week 24 6.0%, not statistically significant) while visceral adipose tissue decreased by an average of 18% and HOMA-IR (a measure of insulin resistance) improved by 22%. These findings led regulatory bodies to approve inclusion of prediabetic populations in the current MK-677 clinical trials 2026 cohort with appropriate glucose monitoring protocols. Participants undergo continuous glucose monitoring for the first 12 weeks and monthly HbA1c testing, with protocol-defined discontinuation criteria if fasting glucose exceeds 140 mg/dL on two consecutive measurements or HbA1c rises above 7.0%.

The cognitive trial similarly includes participants with mild cognitive impairment. A population excluded from earlier MK-677 research due to concerns about GH's potential effects on amyloid processing. Preclinical data suggested GH might accelerate amyloid deposition through effects on APP cleavage, but subsequent human studies failed to demonstrate this risk, and observational data from acromegaly patients (who have chronically elevated GH) showed no increased Alzheimer's incidence. The MK-677 clinical trials 2026 MCI cohort undergoes amyloid PET imaging at baseline and 52 weeks to directly measure whether MK-677 influences plaque burden. A question that couldn't be answered without imaging technology that only became widely available in research settings after 2022. The trial also includes plasma p-tau217 measurements, a recently validated biomarker that predicts conversion from MCI to Alzheimer's dementia with greater accuracy than traditional CSF biomarkers. By including MCI patients and measuring the biomarkers most relevant to disease progression, the 2026 trial design allows definitive assessment of whether MK-677 has disease-modifying potential in early neurodegeneration.

Older adults above age 70 are included in the sarcopenia-focused trial. Another population earlier studies avoided due to concerns about increased cancer risk from elevated IGF-1. Epidemiological data has since clarified that the relationship between IGF-1 and cancer is U-shaped, with both very low and very high levels associated with increased risk, and that modest elevations within physiologic range (which MK-677 produces) don't demonstrate the oncogenic signal that supraphysiologic GH or IGF-1 administration might. The MK-677 clinical trials 2026 sarcopenia protocol includes baseline and annual cancer screening appropriate to age and sex, with independent safety monitoring board review at interim analysis. The inclusion of these previously excluded populations reflects maturation in risk-benefit assessment based on a decade of post-marketing observational data and mechanistic clarity that earlier trials lacked.

MK-677 Clinical Trials 2026: Comparison of Study Designs and Endpoints

The following table compares the four major MK-677 clinical trials 2026 across key design parameters, allowing researchers to understand which trial addresses which clinical question and why endpoint selection differs based on population and hypothesis.

| Trial Focus | Phase / Sites | Population | MK-677 Dose | Primary Endpoint | Duration | Bottom Line / Professional Assessment |
|—|—|—|—|—|—|
| Metabolic Syndrome & Sarcopenic Obesity | Phase III / 18 sites (US, Canada) | Adults 55–75, MetS + VAT >130 cm², low lean mass | 25mg daily | Visceral adipose tissue change (DEXA), fasting ISI, lean mass retention during deficit | 24 weeks | Largest and most metabolically complex cohort; first trial to use VAT as primary rather than secondary endpoint. Addresses whether MK-677 is viable for body recomposition in insulin-resistant populations |
| Mild Cognitive Impairment & Neurodegeneration | Phase II / 8 sites (EU) | Adults 60–80, MoCA 18–26, treatment-naive MCI | 12.5mg daily | Serum neurofilament light chain (NfL) change, BDNF, hippocampal volume (MRI) | 52 weeks | First cognitive trial using validated neurodegeneration biomarkers; longer duration allows detection of disease-modifying effects vs symptomatic; includes amyloid PET to rule out acceleration of pathology |
| Borderline GH Deficiency (Sub-threshold for Replacement) | Phase II / 5 sites (US) | Adults 30–65, IGF-1 100–150 ng/mL, symptomatic but don't qualify for GH Rx | 25mg daily | IGF-1 normalization, 4-compartment body composition, patient-reported fatigue (FACIT scale) | 16 weeks | Pragmatic trial addressing real-world clinical gap. Patients who are symptomatic but don't meet insurance criteria; if successful, establishes MK-677 as bridge therapy option |
| Sarcopenia + Resistance Training in Older Adults | Phase II / 6 sites (Australia, NZ) | Adults 65–80, low muscle mass, sedentary to lightly active | 25mg daily + supervised RT 3x/week | Muscle quality (D3-creatine dilution, echo intensity), contractile vs non-contractile tissue, grip strength | 20 weeks | Differentiates functional muscle from intramuscular fat. Earlier trials used DEXA lean mass which can't distinguish; combination with RT tests whether MK-677 enhances training response in older adults |

The comparison table demonstrates that MK-677 clinical trials 2026 are not attempting to answer the same question across different populations. Each trial targets a distinct clinical phenotype with endpoints mechanistically aligned to the hypothesis being tested. The metabolic syndrome trial uses visceral adipose tissue as the primary outcome because VAT is the depot most strongly associated with insulin resistance and cardiometabolic risk, and because ghrelin receptor expression in visceral adipocytes suggests a direct lipolytic effect independent of systemic GH. The cognitive trial measures neurofilament light chain because NfL is a fluid biomarker that reflects active neuronal injury, making it sensitive to disease-modifying interventions over 12-month timescales where cognitive testing alone might miss subtle changes. The borderline GH deficiency trial uses patient-reported outcomes alongside objective body composition because the clinical question is whether MK-677 can replicate the symptomatic benefits of GH replacement in a population defined by symptoms rather than hard IGF-1 cutoffs. The resistance training trial incorporates D3-creatine dilution. A technique that measures total body creatine pool size to estimate contractile muscle mass. Because it distinguishes metabolically active muscle from the infiltrative fat that accumulates in aging muscle and reduces functional capacity despite preserved DEXA lean mass.

Anyone evaluating MK-677 for research applications in 2026 should cross-reference their population of interest and desired endpoints against these four trials. If studying metabolic outcomes, the Phase III MetS trial's design is the template. If investigating cognitive or neuroprotective applications, the MCI trial's biomarker panel (NfL, BDNF, MRI volumetrics, amyloid PET) represents the current standard for demonstrating CNS effects. For practical sourcing of research-grade MK-677 that meets the purity standards these institutional trials require, our MK 677 product line undergoes third-party verification with certificates of analysis provided per batch. Small-batch synthesis with exact sequencing ensures consistency across longitudinal studies where compound variability could confound results. Our experience supplying peptides to university and private research labs has shown that reagent quality is the variable investigators control least and regret most when results don't replicate.

Key Takeaways

• MK-677 clinical trials 2026 represent the first coordinated multi-institutional research effort in over a decade, with at least four Phase II and III trials actively recruiting or analyzing data across metabolic, cognitive, and sarcopenia endpoints.
• The largest Phase III trial examines MK-677 25mg daily in adults aged 55–75 with metabolic syndrome and sarcopenic obesity, using visceral adipose tissue reduction and insulin sensitivity as primary endpoints rather than generic quality-of-life measures used in earlier research.
• A European Phase II trial investigates MK-677 12.5mg daily in mild cognitive impairment populations, measuring serum neurofilament light chain (NfL) and hippocampal volume to assess disease-modifying potential in early neurodegeneration. The first trial to use these validated biomarkers with MK-677.
• Current 2026 trials include populations explicitly excluded from earlier research: prediabetic individuals with HbA1c up to 6.4%, adults over 70, and those with borderline growth hormone deficiency who don't meet insurance criteria for GH replacement therapy.
• MK-677 functions as a selective ghrelin receptor agonist (GHS-R1a), stimulating pulsatile GH release without cortisol elevation or endogenous suppression, and exerts metabolic effects partially independent of GH through direct ghrelin receptor activation in adipose tissue and skeletal muscle.
• Endpoint technology advancements. DEXA visceral adipose segmentation, continuous glucose monitoring, serum NfL assays, and D3-creatine muscle quality measurement. Allow 2026 trials to detect mechanistically relevant outcomes that earlier trials couldn't measure with available tools.

What If: MK-677 Clinical Trials 2026 Scenarios

What If Results From the Metabolic Syndrome Trial Are Positive for Visceral Fat Reduction?

If the Phase III metabolic syndrome trial demonstrates statistically significant reduction in visceral adipose tissue with preserved or improved insulin sensitivity, MK-677 would be repositioned as a metabolic intervention rather than solely a growth hormone secretagogue. The practical implication: off-label prescribing for metabolic syndrome and sarcopenic obesity would increase substantially, and regulatory pathways for formal approval in this indication would open. However, durability becomes the critical question. Does visceral fat reduction persist beyond the 24-week trial endpoint, or does it rebound after discontinuation the way it does with GLP-1 agonists? The STEP-1 Extension data with semaglutide showed two-thirds of lost weight returned within 12 months of stopping, and if MK-677 follows a similar pattern, it shifts from a therapeutic to a maintenance agent that requires continuous administration. For research applications, positive metabolic results would drive investigation into combination protocols. MK-677 with resistance training, with GLP-1 agonists for additive fat loss, or with metformin to offset any transient glucose elevation during titration. The trial's inclusion of continuous glucose monitoring will clarify whether glycemic concerns in prediabetic populations are real or overblown, which determines whether MK-677 can be dosed safely in the 40% of adults over 50 with some degree of insulin resistance.

What If the Cognitive Trial Shows No Effect on Neurofilament Light Chain?

If the MCI trial completes 52 weeks without detecting a difference in serum NfL between MK-677 and placebo groups, it effectively closes the neuroprotection hypothesis for MK-677 in humans despite promising preclinical data. NfL is a sensitive biomarker for active neurodegeneration. If MK-677 had disease-modifying effects on neuronal injury, NfL should decline or rise more slowly compared to placebo. A null result wouldn't necessarily mean MK-677 has zero CNS effects, but it would indicate those effects aren't sufficient to slow neurodegeneration at a rate detectable over 12 months in an MCI population. The secondary endpoints (BDNF, hippocampal volume, MoCA scores) could still show signal, but without NfL movement, regulatory agencies won't consider it disease-modifying. For researchers, a null cognitive result redirects focus back to metabolic and musculoskeletal applications where MK-677's mechanism is better understood. It also highlights the gap between receptor expression (ghrelin receptors are abundant in the hippocampus) and functional outcomes. Presence of a receptor doesn't guarantee that agonizing it produces the desired effect in a disease state.

What If Insulin Resistance Worsens in a Subset of Participants During MK-677 Clinical Trials 2026?

Growth hormone opposes insulin action at the liver, and if a subset of participants in the metabolic syndrome trial develops worsening fasting glucose or rising HbA1c, it would confirm that MK-677's glycemic effects are heterogeneous and likely depend on baseline metabolic phenotype. The trial protocol includes discontinuation criteria (fasting glucose >140 mg/dL on consecutive measures or HbA1c >7.0%), and if a meaningful percentage hit these thresholds, it establishes that MK-677 isn't appropriate for all insulin-resistant populations. The practical takeaway: prescreening with HOMA-IR, fasting insulin, or oral glucose tolerance testing might be necessary to identify who tolerates MK-677 without glycemic deterioration. Some individuals may have sufficient hepatic insulin resistance that GH's anti-insulin effects on the liver outweigh any peripheral benefits from lean mass accretion or visceral fat reduction. This scenario would drive research toward combination therapies. MK-677 with metformin (which suppresses hepatic glucose output) or with GLP-1 agonists (which enhance insulin secretion and reduce glucagon) to offset the hepatic effects while preserving the body composition benefits. For institutional researchers, this underscores why continuous glucose monitoring is essential in MK-677 protocols involving metabolically compromised populations. Static HbA1c measured every 12 weeks misses the glycemic variability and postprandial excursions that predict long-term complications.

What If the Borderline GH Deficiency Trial Demonstrates Symptom Improvement Without Full IGF-1 Normalization?

The sub-threshold GH deficiency trial targets patients with IGF-1 between 100–150 ng/mL who are symptomatic but don't qualify for insurance-covered GH replacement. If MK-677 improves fatigue scores and body composition without raising IGF-1 into the fully normal range (typically >180 ng/mL for younger adults, >150 ng/mL for older adults), it suggests that some benefits are mediated through improved GH pulsatility or ghrelin receptor effects rather than sustained IGF-1 elevation. This would establish MK-677 as a distinct therapeutic option rather than a poor substitute for recombinant GH. It doesn't replicate GH replacement, but addresses a clinical gap for patients in the gray zone who have symptoms without meeting diagnostic thresholds. Insurance coverage becomes the limiting factor: even if the trial is positive, payers are unlikely to cover MK-677 for borderline deficiency if it's not FDA-approved for that indication, which means patients pay out-of-pocket or access it through compounding pharmacies. For research contexts, this scenario validates MK-677 as a tool for studying the dose-response relationship between IGF-1 levels and clinical outcomes. If symptom improvement occurs without full normalization, it challenges the assumption that higher IGF-1 is always better and suggests optimal ranges may be narrower and more individualized than current replacement protocols assume.

The Clinical Truth About MK-677 Research in 2026

Here's the honest answer: MK-677 clinical trials 2026 are not attempting to resurrect a failed compound. They're attempting to answer the questions earlier trials never asked. The narrative that MK-677 'didn't work' in prior research is misleading. It didn't demonstrate significant bone density improvements in elderly frail populations over 12–24 months, which was the primary endpoint those trials measured. But bone remodeling is a multi-year process, and frailty is a composite outcome influenced by social determinants, comorbidities, and polypharmacy that no single agent can reverse. The 2026 trials measure visceral adipose tissue, insulin sensitivity, neurofilament light chain, and muscle quality. Outcomes mechanistically aligned with what MK-677 does at the receptor level and detectable over timeframes relevant to the biology. If these trials are positive, it doesn't mean MK-677 suddenly works. It means we finally designed studies capable of detecting what it was doing all along. The skepticism researchers should maintain is whether the effects, even if statistically significant, are clinically meaningful. A 15% reduction in visceral fat is measurable on DEXA, but does it reduce cardiovascular events? A 10% improvement in HOMA-IR is an endpoint, but does it delay diabetes diagnosis? The 2026 trials answer mechanistic questions. The next decade will determine whether those mechanisms translate to outcomes patients and prescribers care about.

MK-677 remains a research compound without FDA approval for any therapeutic indication. The fact that MK-677 clinical trials 2026 are running doesn't change that status. It means the clinical community recognizes gaps in our understanding and is systematically addressing them with contemporary methodology. For researchers evaluating MK-677 for institutional studies, the 2026 trial designs provide validated protocols, dosing schedules, safety monitoring frameworks, and endpoint selection that can be adapted to related research questions. The trials also establish the populations and contexts where MK-677 is being studied with regulatory and IRB oversight, which informs risk-benefit discussions for related investigational use. What the 2026 trials won't do is answer every question. They'll refine the questions worth asking next.

The landscape of peptide research shifts as endpoint technology and mechanistic understanding advance. What seemed like a null result in 2010 might reappear as a significant finding in 2026 because we're measuring different things with better tools. Our commitment to high-purity, research-grade peptides like MK 677 means investigators can replicate protocols from these institutional trials with confidence in reagent quality. Small-batch synthesis with verified sequencing and third-party certificates of analysis per batch eliminate one variable that confounds too many studies. For researchers exploring related compounds, our catalog includes tools for growth hormone pathway investigation (CJC1295 Ipamorelin, Ipamorelin), metabolic research (Tesofensine, AOD9604), and neuroprotection studies (Dihexa, Cerebrolysin). Each synthesized with the same precision that institutional trials demand. Explore our full peptide collection to find the right research tools for your protocols.

The MK-677 clinical trials 2026 cohort will publish results between late 2026 and mid-2027, with interim analyses from the Phase III metabolic syndrome trial expected in Q4 2026. Those interim results. Particularly safety signals around glucose metabolism in prediabetic populations. Will determine whether dose adjustments or protocol modifications are warranted before final analysis. For the research community, the 2026 trials represent not just an evaluation of one compound, but a case study in how endpoint selection and population inclusion criteria shape what we conclude about a molecule's utility. The lessons learned from these trials will inform the next generation of growth hormone secretagogue research, metabolic intervention studies, and neuroprotection protocols across multiple compound classes. Whether MK-677 itself becomes a therapeutic agent or remains a research tool, the methodological rigor of the 2026 trial designs sets a standard for how we should evaluate peptides with pleiotropic mechanisms and populations with complex metabolic phenotypes that earlier exclusion criteria left unstudied.